



GRANT AGREEMENT

This Grant Agreement ("**Agreement**") is entered into as of 5th of July 2018 ("**Effective Date**") by and between Novartis Healthcare A/S, Reg. No. 20575786, a company incorporated under the laws of Denmark, located at Edvard Thomsens Vej 14, DK-2300 Copenhagen S, Denmark ("**Novartis**") and NETPA Reg. No. 33008686, a Patient Organization incorporated under the laws of Denmark, located at Langebjerg 16, 4. Th, 2850 Nærum, ("**Grant Recipient**"). Novartis and Grant Recipient may hereinafter be referred to individually as a "**Party**" and collectively as the "**Parties**".

WHEREAS, Grant Recipient has specifically requested Novartis' financial contribution in order to support the Grant Activity (as defined in Exhibit A), through a Grant Request Letter, which is attached hereto as Exhibit B;

WHEREAS, in accordance with the Grant Request Letter mentioned above, Novartis wishes to support the Grant Activity with the Grant Amount (as defined in Exhibit A); and

WHEREAS, Grant Recipient accepts the Grant Amount subject to the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:

1. GRANT BY NOVARTIS

- 1.1 **Grant.** Novartis will provide the Grant Amount as set forth in Exhibit A solely to support Grant Recipient in performing the Grant Activity as set forth in Exhibit A.
- 1.2 **Statement of Purpose.** The Grant Activity is for scientific and/or educational purposes only and will not promote Novartis' products, directly or indirectly. The Grant Amount is not being given in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, influence or provide favorable formulary status for any of Novartis' products. The Grant Amount is based upon a budget provided to Novartis by Grant Recipient reflecting a good faith estimate of the actual cost of the Grant Activity. The Grant Amount has not been determined in a manner that takes into account the volume or value of referrals or business, if any, generated between Novartis and Grant Recipient or any of their respective officers, directors, employees, agents, affiliates, parents or subsidiaries.
- 1.3 **Novartis Responsibility.** Grant Recipient agrees that Novartis' responsibility is solely to provide the Grant Amount. Novartis will not be liable to Grant Recipient or to any other person for the Grant Activity or the use of the Grant Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Grant Recipient to return the Grant Amount and take other corrective action if Grant Recipient breaches this Agreement.

2. OBLIGATIONS OF GRANT RECIPIENT

2.1 Use of Grant Amount.

- (a) Grant Recipient shall use the Grant Amount solely for the Grant Activity and shall not use the Grant Amount for any activity that is inconsistent with, or prohibited by any law, rule or regulation. The Grant Recipient undertakes to independently contact Novartis in the event any part of the



Grant Amount has not been used for the Grant Activity so that such amount can be refunded to Novartis without undue delay.

- (b) Grant Recipient will comply with (and shall be solely responsible for any failure to comply with) all relevant laws, rules and regulations (including any code of practice or other guidelines generally followed by pharmaceutical companies in the relevant country) in connection with the Grant Activity. Grant Recipient warrants that the Grant Activity is compliant with all such requirements.
- (c) Grant Recipient is solely responsible for the manner in which the Grant Amount is disbursed, recorded and accounted and for all contractual and other relationships with third parties relating to the Grant Activity and the use of the Grant Amount. Any claims for payment from third parties involved in the Grant Activity are the sole responsibility of Grant Recipient and Novartis will not fund any additional amounts for the Grant Activity.

2.2 **Objectivity & Balance.**

- (a) The Grant Activity will be independent, non-promotional and free from commercial influence or bias.
- (b) If the Grant Activity involves the discussion of Novartis products, or the comparison of Novartis products with other products, that discussion and/or comparison must be objective, balanced, accurate, not misleading or deceptive and in compliance with all applicable laws, rules and regulations. Where appropriate, the Grant Activity will include a discussion of multiple treatment options, and will not focus on a single product.
- (c) Grant Recipient will ensure that any titles or overview information relating to the Grant Activity will fairly and accurately represent the scope of the planned activity.
- (d) If required, Grant Recipient is responsible for selection of presenters, moderators and collaborators for the Grant Activity. Novartis will not control the planning, content, speaker selection or execution of any Grant Activity. If Novartis suggests presenters, moderators or collaborators, Grant Recipient will record the role of Novartis in making the suggestion, seek other sources and make a final selection based on balance and independence.

2.3 **Disclosure of Financial Relationships.**

- (a) Grant Recipient will: (i) disclose, to all audiences and in all publications relating to the Grant Activity, that Novartis has provided a grant to support the Grant Activity; (ii) acknowledge support from Novartis in brochures, syllabi, and other materials related to the Grant Activity; and (iii) disclose any other relationships Novartis has with any individual speakers, moderators, collaborators or Grant Recipient which a reasonable and ethical person would expect to be disclosed.
- (b) Novartis may disclose publicly the financial and non-financial support provided to Grant Recipient, including, without limitation, the Grant Recipient's identity, the Grant Amount and purpose of the support.

2.4 **Ancillary Activities.**

- (a) If the Grant Activity occurs as part of an overall activity that includes commercial activities, such activities will neither influence planning nor interfere with the Grant Activity. No commercial



activities will be permitted in the same room as an educational activity, unless (i) this is allowed in the country in which the activity will take place and (ii) only to the extent that such commercial activity does not interfere with the purpose of the Grant Activity.

- (b) The scheduling of meals and/or receptions, if any, in connection with any portion of the Grant Activity is at the sole discretion of Grant Recipient. Meals and/or receptions, if any, will be modest and conducive to the Grant Activity, and the amount of time at the meals or receptions will be clearly subordinate to the overall amount of time.
- (c) **Reconciliation of Expenses.** At the conclusion of the Grant Activity, Grant Recipient will provide to Novartis a reconciliation of the actual expenses versus estimated expenses and will issue a refund to Novartis for any portion of the Grant Amount not incurred in the implementation of the Grant Activity. In addition, Grant Recipient will retain appropriate records of the Grant Activity and the use of the Grant Amount and will provide evidences (as further specified in Exhibit A) to Novartis to document that the Grant Amount has been used in accordance with this Agreement.

3. GENERAL

- 3.1 **Entire Agreement.** This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail.
- 3.2 **Governing Law and Jurisdiction.** This Agreement shall be governed by and construed under the laws of Denmark, without giving effect to the conflicts of laws provision thereof. Any dispute or claim arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, is to be brought before the Maritime and Commercial Court in Copenhagen or, if this court is not competent, before a competent court of law in the Kingdom of Denmark.
- 3.3 **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.



NOVARTIS HEALTHCARE A/S

By: Elisabet Oladottir

Date: 05-Jul-2018 | 9:06:57 AM EDT

Signature: DocuSigned by:
Elisabet Oladottir
6460C1B340804AD...

NETPA

By: Lars Birk

Date: 06-Jul-2018 | 5:45:01 AM EDT

Signature: DocuSigned by:
Lars Birk
D06A2E97BBF74FF...

By: Tarje Bergdahl

Date: 06-Jul-2018 | 2:50:39 AM EDT

Signature: DocuSigned by:
Tarje Bergdahl
EC719E55748A44F...

By: Johannes Eis

Date: 06-Jul-2018 | 4:15:13 AM EDT

Signature: DocuSigned by:
Johannes Eis
2077C018702C49D...



EXHIBIT A

GRANT AMOUNT & GRANT ACTIVITY

Grant Amount: **60.000** DKK

Grant Activity: The grant is to fund NETdagen 2018 on the 10th of November 2018. The purpose of NETdagen is to have a meeting for patients and their families. The meeting gives the patients the possibility to hear about the latest research within the NET area from physicians from the hospitals treating NET. There is also the possibility to network with other patients. NETPA also gets the opportunity to promote themselves and recruit new members to the organisation. The grant can be used to pay for the meeting package per participant, transport and accommodation for speakers and board and materials. The grant can't be used to pay for gifts to speakers.

Evidences must be provided to Novartis upon completion of the Grant Activity:

The grant recipient is required to confirm to Novartis within two months from conducting the activity that the grant has been used for the purpose intended by submitting the final budget of the meeting.

The Grant amount is payable against the corresponding invoice within sixty (60) days of its receipt and at the end of a calendar month.

The invoice shall include all details (including a Purchase Order Number) as specified in the Purchase Order received by Grant Recipient at the following email address: johannes.eis@gmail.com



EXHIBIT B

GRANT REQUEST LETTER



København den 8. maj 2018

Novartis Healthcare A/S
Edvard Thomsens vej 14, 3. sal
2300 København S

Att.: Disease Area Manager Evy Skovhaur

Ansøgning om støtte til afholdelse af den Internationale NET CANCER dag den 10. november 2018 i Århus.

I henhold til tidligere afholdt møde fremsender vi hermed vores ansøgning om støtte til afholdelse Netdagen 2018.

Som nævnt i møderne er vi i den situation at vi ikke kan få støtte fra Kræftens Bekæmpelse i dette år. Derfor henvender vi os til medicinalindustrien ved virksomhederne Ipsen og Novartis.

Det er af afgørende betydning for patientforeningen Netpa Danmark, at vi på denne dag får mulighed for at markere os i offentligheden, ligesom det er væsentligt overfor vores medlemmer af foreningen samt Net cancerpatienter og pårørende i det hele taget. Her får deltagerne mulighed for at høre om det sidste nye, der er kommet om behandling med mere af NET.

Fra hospitalsverdenen deltager en række læger og forskere uden vederlag.

For at så mange som muligt deltager i Netdagen har vi valgt at dagen er gratis for deltagere og deres pårørende.

Budgettet er udarbejdet som et forventet maksimum baseret på tidligere erfaringer. Vi har dog konstateret at der er en mindre tilslutning til lignende arrangementer når de holdes i Aarhus frem for i København, hvorfor vi ikke forventer en overskridelse af budgettet, nærmere det modsatte. Det er hensigten, at de faktiske omkostninger fordeles ligeligt mellem Ipsen og Novartis.

Såfremt vores ansøgning imødekommes vil det fremgå af det materiale der udleveres til deltagerne at denne konference er sponsoreret af de støttende virksomheder.



Vi ser frem til jeres positive behandling af denne ansøgning.

Med venlig hilsen

Lars Birk
Formand for Patientforeningen